Lantus Solostar Injection, Solution
Product Images NDC 0088-2219

36 FDA label images from Sanofi-aventis U.s. Llc · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 36 technical images submitted to the FDA as part of the official labeling for Lantus Solostar (NDC 0088-2219). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sanofi-aventis U.s. Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Figure 1 (D5e07a0c 7e14 4756 9152 9fea485d654a 01)

Figure 1 (D5e07a0c 7e14 4756 9152 9fea485d654a 01)
A line graph comparing glucose infusion rates over time after subcutaneous injection for Lantus (insulin glargine) and NPH insulin. The x-axis represents time in hours, and the y-axis shows glucose infusion rate in mg/kg/min. The graph depicts data for 20 subjects each, with markers indicating the end of observation periods.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 02)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 02)
An instructional illustration showing a close-up of hands removing the cap from a vial, typically demonstrating how to prepare an injection vial for use.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 03)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 03)
An instructional line drawing showing a hand peeling off a protective cap from the top of a vial, likely demonstrating the initial step in preparing an injection vial.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 04)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 04)
An instructional illustration showing a person holding an insulin syringe filled with liquid, drawing solution from a vial. The image demonstrates the correct technique for preparing an injection, including drawing fluid into the syringe by pulling the plunger back while holding the vial upside down.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 05)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 05)
An instructional illustration depicting the preparation of a syringe with medication. A hand is shown drawing solution from a vial into a syringe, demonstrating how to fill the syringe prior to injection.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 06)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 06)
An instructional line drawing depicting a hand holding a syringe or pen-type injector with the thumb pressing a plunger or button, demonstrating usage technique for an injection device. The image suggests how to administer a subcutaneous injection, likely related to Lantus insulin glargine injection.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 07)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 07)
An instructional illustration showing two hands handling a syringe filled with medication. One hand is holding the syringe upright while the other hand is positioned near the syringe plunger, suggesting preparation for injection or removal of air bubbles.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 08)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 08)
An instructional diagram showing recommended subcutaneous injection sites on the human body for Lantus injection solution. The highlighted areas include the upper arms, stomach, and thighs, indicating where the insulin glargine injection can be administered.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 09)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 09)
A black-and-white line drawing showing a close-up instructional illustration of a person injecting medication subcutaneously into the side of their finger area. The image focuses on the positioning of the hands and injection site.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 10)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 10)
An instructional illustration showing a hand preparing to inject medication subcutaneously into a finger using a syringe, with an arrow indicating the injection site or action.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 11)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 11)
An instructional anatomical diagram showing recommended insulin injection sites for Lantus (insulin glargine) solution. The highlighted areas for subcutaneous injection include the upper arms, stomach, and thighs.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 12)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 12)
An illustration of a Lantus SoloStar pen for insulin glargine injection 100 IU/mL. It shows the pen cap, pen needle components (outer needle cap, inner needle cap, protective seal, needle), and the pen body featuring the insulin reservoir, rubber seal, dosage scale, dose window, and injection button.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 13)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 13)
Lantus 100 units/mL (insulin glargine injection) pen device for subcutaneous use. The label indicates it is a single-patient use solution, manufactured by sanofi-aventis U.S. LLC, with clear dosage strength marking on the pen body.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 14)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 14)
Lantus 100 IU/mL injection solution pen for subcutaneous use, with a visible lot number (123XY) and expiration date (October 31, 2029), labeled by sanofi-aventis U.S. LLC. The image shows the side of the pen device featuring key identification details next to a barcode.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 15)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 15)
An instructional illustration showing hands holding the Lantus insulin glargine 100 units/mL injection pen. The image depicts the removal of the pen cap by pulling it straight off, indicated by a blue arrow pointing away from the pen.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 16)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 16)
Lantus SoloStar insulin glargine injection, 100 units/mL, solution for subcutaneous use. The image shows a prefilled pen injector with dosage markings visible from 0 to 300 units. The label indicates it is for single patient use, manufactured by sanofi-aventis U.S. LLC.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 17)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 17)
An instructional illustration showing hands cleaning the rubber stopper of a pen injector with a sterile wipe before administering the injection. The image emphasizes preparation for subcutaneous injection of a solution, consistent with instructions for Lantus insulin glargine injection.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 18)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 18)
An instructional line drawing showing two hands opening the cap of a small cylindrical vial or cartridge. The illustration appears to demonstrate how to remove the protective cover from the vial, likely for preparation of an insulin glargine injection.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 19)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 19)
An instructional diagram showing proper removal of the cap from a Lantus insulin glargine injection pen. The illustration demonstrates pulling the cap straight off the pen with two hands and includes a cautionary inset indicating not to twist the cap during removal.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 20)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 20)
An instructional illustration showing a hand holding a Lantus insulin glargine injection pen with visible dosing markings. Another hand is depicted placing or removing a protective cap from the needle on a surface. The image demonstrates handling or preparing the injection pen for subcutaneous administration.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 21)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 21)
An instructional illustration showing a hand removing a protective cap from a bottle, with a syringe held nearby, indicating preparation for injection or medication withdrawal. The image highlights handling and opening medication packaging.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 22)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 22)
Illustration showing a person holding a Lantus insulin glargine 100 units/mL injection pen, adjusting the dose by turning the dose selector. A close-up inset highlights the dose window on the pen displaying the number 2.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 23)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 23)
Illustration showing a hand operating a syringe, with a zoom-in on the needle tip expelling a small spray of liquid. The image likely demonstrates proper syringe usage or priming technique for an injectable drug.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 24)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 24)
Lantus Solostar pen for injection with insulin glargine 100 units/mL. The image shows the pen device, including the needle, dose window displaying 10 units, and the label identifying it as Lantus Solostar, a subcutaneous injection by sanofi-aventis U.S. LLC. The pen is designed for single patient use.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 25)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 25)
An instructional illustration showing hands holding a Lantus insulin glargine 100 units/mL pen injection. The image demonstrates rotating the dose knob on the pen to set or adjust the insulin dose.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 26)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 26)
An illustration showing a close-up of a dose selector window on a pen injector, indicating a dose of 20 units selected. The pen is designed for subcutaneous injection, consistent with insulin glargine (Lantus) use.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 27)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 27)
An illustration showing a close-up of a dial indicator on an insulin injection pen, with the dose set to 21 units. The dial displays numbers from 20 to 22, highlighting precise dosage adjustment for subcutaneous injection.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 28)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 28)
Illustration showing a hand holding a Lantus insulin glargine injection pen, demonstrating how to pull the insulin dose selector to set the dosage. The pen is designed for subcutaneous injection, with a visible dial displaying dose units. An arrow indicates the direction to pull for dose adjustment.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 29)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 29)
Instructional illustration showing proper handling of an insulin injection pen for Lantus (insulin glargine) 100 units/mL. It highlights correct thumb placement on the dose selector, indicating turning counterclockwise, with a close-up circle demonstrating the thumb position on the correct grip area, and an adjacent circle marking the incorrect grip area with a red cross.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 30)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 30)
An instructional diagram showing a hand holding a Lantus insulin glargine injection pen in a subcutaneous injection position. The image highlights holding the injection for 10 seconds after administration, indicated by a clock icon with "10 secs".*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 31)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 31)
An instructional illustration showing how to attach the needle to a Lantus insulin glargine 100 [iU]/mL injection pen. It depicts two hands, one holding the insulin pen cartridge and the other attaching the needle cap to the pen tip, with a blue arrow indicating the direction of attachment.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 32)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 32)
An instructional illustration showing how to prepare a Lantus insulin glargine 100 IU/mL injection solution cartridge for use. The image depicts a hand twisting and pulling off the protective cap from the cartridge tip. The cartridge is marked with a graduated scale for dosage measurement.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 33)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 33)
An instructional illustration showing a person's hands removing a bottle cap and holding a small vial above the open bottle, indicating the step of adding or mixing contents in a container.*
FDA Label Image

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 34)

Figure (D5e07a0c 7e14 4756 9152 9fea485d654a 34)
Illustration showing two hands holding a Lantus insulin glargine injection pen. One hand grips the pen body, while the other is pulling the pen cap off, indicated by a blue arrow pointing to the left, demonstrating how to remove the cap from the injection pen prior to use.*
FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Principal Display Panel (10 mL Vial Carton)
Packaging label for Lantus insulin glargine injection 100 units/mL (U-100) by sanofi-aventis U.S. LLC. The label indicates it is for subcutaneous injection only, use with U-100 syringe, and contains a 10 mL multiple-dose vial. Storage instructions and usage warnings are included, along with the NDC 0088-2220-33.*
FDA Label Image

Principal Display Panel (3 mL Pen Carton)

Principal Display Panel (3 mL Pen Carton)
Packaging label for Lantus SoloStar insulin glargine injection solution, 100 units/mL (U-100). The label indicates it is for single patient use only and contains five 3 mL prefilled pens. It specifies subcutaneous injection, to be used only if clear and colorless, and not to mix with other insulins. The labeler is sanofi-aventis U.S. LLC. A detailed image of the prefilled pen device is shown at the bottom.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.